Introduction: Response to neoadjuvant chemotherapy for locally advanced breast cancer can be correlated with long-term outcomes. Surrogate end-point biomarkers may be used to assess response to the treatment. Most reported studies assessed the effects of combination chemotherapy. We assessed the feasibility of obtaining serial core breast biopsies, and correlated rates of apoptosis, proliferation, and expression of related proteins at baseline, during, and after neoadjuvant single agent chemotherapy for locally advanced breast cancer with response. Experimental Design: Women with a histologically confirmed unresected T3 or T4 infiltrating carcinoma of the breast were eligible. The first 20 patients received three cycles of doxorubicin 90 mg/m2 followed by three cycles of paclitaxel 250 mg/m2, or the reverse. Nine women received four cycles of each (doxorubicin 60 mg/m2 and paclitaxel 175 mg/m2). Cycles were administered 14 days apart with filgastrim. Endq points included: (a) clinical and pathological response; (b) serial apoptotic [terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling] and proliferation (immunohistochemistry, IHC) rates; and (c) expression (IHC) of estrogen receptor, HER2, bcl2, and p53. Results: From April 1997 to June 2001, 29 women were randomized. Twelve patients (42%) had a clinical complete response (cCR), and 16 (55%) had a clinical partial response. Five women (17%) had a pathological complete response, 7 (24%) had microscopic residual disease, and 17 (58%) had macroscopic residual disease. Higher baseline apoptosis and proliferation were associated with an improved pathological response (P = 0.006 and 0.003, respectively). Among 14 evaluable patients, apoptosis increased in women who had a cCR to the first agent but not in women without a cCR. Estrogen receptor-positive patients had a worse pathological response (P = 0.004). Conclusions: The selected regimen is efficacious. It is feasible to obtain serial core biopsies that are informative for studies of apoptosis and IHC. This clinical design can serve as a model for combining standard chemotherapy and novel agents.
|Original language||English (US)|
|Number of pages||10|
|Journal||Clinical Cancer Research|
|Issue number||1 I|
|State||Published - Jan 1 2003|
ASJC Scopus subject areas
- Cancer Research